Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, and Placebo-controlled Parallel Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of HSK39297 Tablets in Treatment of Patients With Primary IgAN

NCT07390123 is registered in ClinicalTrials.gov with Haisco Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT07390123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07390123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, and Placebo-controlled Parallel Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of HSK39297 Tablets in Treatment of Patients With Primary IgAN
Lead sponsor
Haisco Pharmaceutical Group Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
April 7, 2026
Completion date
July 31, 2028
Enrollment
370 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

iga nephropathy (igan)